Page 4«..3456..1020..»

Is ZIOPHARM Oncology Inc (ZIOP) Building Momentum? – FLBC News

Posted: August 19, 2017 at 2:43 pm

The Awesome Oscillator for ZIOPHARM Oncology Inc (ZIOP) is showing a five day consistent downtrend, signaling building market momentum for the shares. Author and trader Bill Williams created The Awesome Oscillator Indicator (AO) and outlined the theory and calculation in his book New Trading Dimensions. The indicator shows the difference between two simple moving averages that can help define moving strength of the market. Bill Williams developed this indicator on the basis of earlier existed MACD and made a number of changes. The Awesome Oscillator subtracts a 34 period simple moving average (SMA) from a 5 period SMA. It illustrates whats happening to the market driving force at the present moment. The interpretation is similar to MACD including buying when the oscillator crosses through the zero line to the upside and selling when it crosses back below. Of course, this will result is many false signals in flat or choppy markets. As with most indicators, the AO is best used alongside additional technical signals.

Technical traders often make a point of keeping an eye on the ATR or Average True Range as well. Currently, ZIOPHARM Oncology Inc (ZIOP) has a 14-day ATR of 0.25. The Average True Range is an investor tool used to measure stock volatility. The ATR is not used to figure out price direction, just to measure volatility. The ATR is an indicator developed by J. Welles Wilder. Wilder has developed multiple indicators that are still quite popular in todays investing landscape. The general interpretation of the ATR is the higher the ATR value, the higher the volatility.

The Williams Percent Range or Williams %R is another technical indicator worth checking out. ZIOPHARM Oncology Inc (ZIOP) currently has a 14 day Williams %R of -94.05. The Williams %R fluctuates between 0 and -100 measuring whether a security is overbought or oversold. The Williams %R is similar to the Stochastic Oscillator except it is plotted upside-down. Levels above -20 may indicate the stock may be considered is overbought. If the indicator travels under -80, this may signal that the stock is oversold. Chart analysts may also use the indicator to project possible price reversals and to define trends.

The Average Directional Index or ADX is technical analysis indicator used to discern if a market is trending or not trending. The ADX alone measures trend strength but not direction. Using the ADX with the Plus Directional Indicator (+DI) and Minus Directional Indicator (-DI) may help determine the direction of the trend as well as the overall momentum. Many traders will use the ADX alongside other indicators in order to help spot proper trading entry/exit points. Currently, the 14-day ADX for ZIOPHARM Oncology Inc (ZIOP) is 18.33. Generally speaking, an ADX value from 0-25 would indicate an absent or weak trend. A value of 25-50 would indicate a strong trend. A value of 50-75 would signal a very strong trend, and a value of 75-100 would indicate an extremely strong trend.

Traders may be leaning on technical stock analysis to help with investing decisions. ZIOPHARM Oncology Inc (ZIOP) currently has a 14-day Commodity Channel Index (CCI) of -147.32. Despite the name, CCI can be used on other investment tools such as stocks. The CCI was designed to typically stay within the reading of -100 to +100. Traders may use the indicator to determine stock trends or to identify overbought/oversold conditions. A CCI reading above +100 would imply that the stock is overbought and possibly ready for a correction. On the other hand, a reading of -100 would imply that the stock is oversold and possibly set for a rally.

Traders are paying renewed attention to shares of ZIOPHARM Oncology Inc (ZIOP). The current 14-day RSI is presently sitting at 34.19, the 7-day is 25.09, and the 3-day is 8.51. The RSI, or Relative Strength Index is a popular oscillating indicator among traders and investors. The RSI operates in a range-bound area with values between 0 and 100. When the RSI line moves up, the stock may be experiencing strength. The opposite is the case when the RSI line is heading lower. Different time periods may be used when using the RSI indicator. The RSI may be more volatile using a shorter period of time. Many traders keep an eye on the 30 and 70 marks on the RSI scale. A move above 70 is widely considered to show the stock as overbought, and a move below 30 would indicate that the stock may be oversold. Traders may use these levels to help identify stock price reversals.

View original post here:
Is ZIOPHARM Oncology Inc (ZIOP) Building Momentum? – FLBC News

Posted in Oncology | Comments Off on Is ZIOPHARM Oncology Inc (ZIOP) Building Momentum? – FLBC News

Could City Lights Raise Breast Cancer Risk? – WebMD

Posted: at 2:42 pm

By Randy Dotinga

HealthDay Reporter

THURSDAY, Aug. 17, 2017 (HealthDay News) — New research reveals an unexpected potential risk factor for breast cancer: city lights.

The Harvard Medical School study found an association between living in areas with high amounts of ambient nighttime light and slightly increased odds for breast cancer in younger women who smoke.

“In our modern industrialized society, artificial lighting is nearly ubiquitous. Our results suggest that this widespread exposure to outdoor lights during nighttime hours could represent a novel risk factor for breast cancer,” study author Peter James said in a Harvard news release. He’s assistant professor of population medicine at Harvard’s Pilgrim Health Care Institute.

As the investigators explained, earlier research had suggested that high levels of exposure to light at night disrupts the body’s internal clock. In turn, that might lower levels of a hormone called melanin which, in turn, might boost the risk of breast cancer.

Testing the theory further, James’ group tracked almost 110,000 U.S. women, followed as part of a long-term study of nurses from 1989-2013.

The researchers used nighttime satellite images and records of night shift work to help figure out the amount of nighttime light each woman might have been exposed to.

The study wasn’t designed to prove cause and effect. However, the Harvard group found that breast cancer levels in premenopausal women who currently smoked or had smoked in the past grew by 14 percent if they were in the 20 percent deemed to have had the most exposure to outdoor light at night.

Furthermore, as levels of outdoor nighttime light went up, so did the likelihood of breast cancer for this subgroup of women, James’ team said.

Older women, and women who’d never smoked, did not seem affected, the researchers said.

The study also found evidence that working night shifts might boost the breast cancer risk.

Given that millions of younger women have little control over the amount of nighttime ambient light they’re exposed to, what, if anything, should be done?

One expert in breast cancer care said it’s just too soon to take anything concrete from this research.

“The findings in this study have to be taken with caution,” said Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City. “Although circadian rhythm disruption may be a factor in increasing the risk of cancer, it could be other factors related to working at night as well.”

For example, she said, “women who work night shifts may not eat well or exercise, both of which affect breast cancer risk. Also, the study found the risk greatest in smokers — which leads one to believe these women might not be living as healthy a lifestyle as the group that was sleeping at night.”

Overall, Bernik said, “more insight as to the root cause of the increased rate of cancer in night owls is needed.”

The study was published Aug. 17 in the journal Environmental Health Perspectives.

WebMD News from HealthDay

SOURCES: Stephanie Bernik, M.D., chief, surgical oncology, Lenox Hill Hospital, New York City; Harvard T.H. Chan School Of Public Health, news release, Aug. 17, 2017

Read the original:
Could City Lights Raise Breast Cancer Risk? – WebMD

Posted in Cancer | Comments Off on Could City Lights Raise Breast Cancer Risk? – WebMD

Fatty Foods May Up Cancer Risk in Thinner Women – WebMD

Posted: at 2:42 pm

By Amy Norton

HealthDay Reporter

THURSDAY, Aug. 17, 2017 (HealthDay News) — Women who eat a lot of high-calorie foods may face a slightly higher risk of obesity-related cancers — even if they remain thin, a new study suggests.

The study, of more than 92,000 U.S. women, found those who favored high-calorie, low-nutrient foods had a 10 percent higher risk of cancers linked to obesity. These include processed foods like chips, fast foods and sweets.

The list of malignancies included breast, colon, ovarian, kidney and endometrial cancers. Obesity is considered one of many risk factors for those diseases.

There was a catch, though, the study found. A penchant for high-calorie food was tied to cancer risk only among women who were of normal weight.

Researchers called the findings “novel” and somewhat unexpected. Going into the study, they’d hypothesized that any link between calorie-dense diets and cancer would be strongest among obese women.

But the results suggest that staying trim, alone, is not enough to curb the risk of obesity-related cancers, said lead researcher Cynthia Thomson.

“I think when we say that certain cancers are associated with obesity, people who are normal-weight think, ‘So I’m OK,’ ” said Thomson, a professor at the University of Arizona’s Zuckerman College of Public Health.

But, she added, being thin doesn’t mean you are “metabolically healthy” — which means having normal blood sugar, cholesterol and triglyceride levels, for instance.

That “metabolic dysregulation” might partly explain the higher cancer risk seen in this study, Thomson and her colleagues speculated.

“That may be true,” agreed Marji McCullough, strategic director of nutritional epidemiology for the American Cancer Society.

McCullough, who was not involved in the study, also pointed to another possibility. People who eat lots of calorie-laden foods tend to eat few “plant-based foods,” including fruits, vegetables, beans and whole grains.

That means they’ll be low on the fiber, vitamins and other nutrients that may help curb the risk of certain cancers, McCullough said.

What’s wrong with calorie-dense foods? By definition, they pack a lot of calories relative to their weight.

That’s not necessarily bad, McCullough noted. “Some are healthful,” she said, “like olive oil and nuts.”

But many calorie-dense foods are relatively low in nutrients. In general, processed foods (chips, crackers and prepared dressings), fast foods (cheeseburgers and pizza), and candy bars fall into that category.

McCullough pointed to the example of pretzels. A person can end up eating a huge bowl of them before feeling satisfied — downing a lot of calories with little nutritional value.

The new findings are based on more than 92,000 women who were ages 50 to 79 at the outset of the trial.

When they entered the study, the women gave detailed information on their eating habits. From that, Thomson’s team calculated the calorie-density of each woman’s typical diet.

Over 15 years, just under 9,600 women developed a cancer that has been tied to obesity — most often breast cancer, followed by colon cancer.

While the study only found an association, those odds of developing cancer were slightly higher in general among women who favored calorie-laden foods.

When the researchers dug deeper, though, the link was only apparent among women who were normal weight.

Those who ate the most calorie-dense foods (enough to land them in the top 40 percent) were 12 to 18 percent more likely to develop an obesity-related cancer, versus women who ate relatively few of those foods.

That was with other factors taken into account — including age, overall health, and smoking, drinking and exercise habits.

But if diet quality matters, why was there no link among heavier women?

One possibility, McCullough said, is that the effects of their excess weight “overwhelmed” any impact of diet itself.

Thomson pointed to another possibility: Normal-weight women who ate a lot of calorie-dense foods may have had a more dramatic weight gain as they grew older. The researchers had some information on weight gain, but not for the entire study period, she noted.

Whatever the reasons, the bottom line is fairly simple, according to McCullough. “Eat more plant-based foods,” she said.

That’s what the American Cancer Society and other groups already recommend for the sake of overall good health, McCullough noted.

“This study supports what we’ve been saying,” McCullough said. “There are plenty of reasons to eat a plant-based diet, beyond just weight control.”

The findings were published Aug. 17 in the Journal of the Academy of Nutrition and Dietetics.

WebMD News from HealthDay

SOURCES: Cynthia Thomson, Ph.D., R.D.N., professor, health promotion sciences, Zuckerman College of Public Health, University of Arizona, Tucson; Marji McCullough, Sc.D., R.D., strategic director, nutritional epidemiology, American Cancer Society, Atlanta; Aug. 17, 2017, Journal of the Academy of Nutrition and Dietetics, online

See the original post here:
Fatty Foods May Up Cancer Risk in Thinner Women – WebMD

Posted in Cancer | Comments Off on Fatty Foods May Up Cancer Risk in Thinner Women – WebMD

Q&A: Screening for colorectal cancer – Philly.com

Posted: at 2:42 pm

Q: I just turned 30. Should I get screened for colorectal cancer?

A: Earlier this month, a study from the American Cancer Society found an increase in colon and rectal cancers among young adults in every generation since 1970. Researchers were not sure of the reason for the increase, but stated that more education among younger adults was clearly needed, to help reduce delays in diagnoses.

The United States Preventive Services Task Force recommends that all adults over 50 get a routine screening with colonoscopy. However, there are some groups who would benefit from earlier screenings, such as those who have:

Those who have familial adenomatous polyposis should start colorectal cancer screenings as adolescents. Those with Lynch syndrome should start getting screened in their 30s. Irritable bowel disease does not have any clear screening guidelines, but during an appointment with a gastroenterologist, a patient will typically undergo a colonoscopy to help with IBD diagnosis.

According to the American College of Gastroenterology, patients with first-degree relatives should start receiving colonoscopies at age 40, or 10 years younger than the earliest diagnosis in their family whichever comes first.

Even if you arent part of these high-risk groups, you should be aware of these signs and symptoms of colorectal cancer:

If you are experiencing any of these symptoms regardless of your age talk to your doctor immediately.

Erik Polan, DO, is an internal medicine physician at Philadelphia College of Osteopathic Medicine.

Published: August 19, 2017 3:01 AM EDT

We recently asked you to support our journalism. The response, in a word, is heartening. You have encouraged us in our mission to provide quality news and watchdog journalism. Some of you have even followed through with subscriptions, which is especially gratifying. Our role as an independent, fact-based news organization has never been clearer. And our promise to you is that we will always strive to provide indispensable journalism to our community. Subscriptions are available for home delivery of the print edition and for a digital replica viewable on your mobile device or computer. Subscriptions start as low as 25 per day.We’re thankful for your support in every way.

Read the original here:
Q&A: Screening for colorectal cancer – Philly.com

Posted in Cancer | Comments Off on Q&A: Screening for colorectal cancer – Philly.com

Nationals owner Mark Lerner had leg amputated to remove cancer – ESPN

Posted: at 2:42 pm

Mark Lerner, a principal owner of the Washington Nationals, is recovering from having his left leg amputated last week after doctors determined they had no choice following previous surgeries and radiation for cancer in the limb.

Lerner, son of Ted Lerner, the managing principal owner of the Nationals, said in a letter to The Washington Post that he was now cancer-free.

“With my doctors and medical team, we decided that amputation of that leg was my best choice to maintain the active and busy lifestyle that I have always enjoyed,” the 63-year-old Lerner said in the letter. “The limb was removed in early August and I’m healing well, cancer-free, and looking forward to my eventual new prosthetic.”

According to The Post, the usually present Lerner has been mostly absent at Nationals home games this season and was last in attendance July 30.

The Nationals placed outfielder Brian Goodwin on the 10-day disabled list Wednesday with a left groin strain. The move is retroactive to Aug. 14.

Stephen Strasburg didn’t think he needed to go on a rehab start, so he made quick work of his brief trip to the minors.

Bryce Harper does not have any ligament or tendon damage in his injured left knee, but the Nationals All-Star is out indefinitely because of a significant bone bruise.

2 Related

“I know you recognize that only something really challenging would have kept me from my favorite seat at the ballpark these past months,” Lerner said in the letter.

Ted Lerner is a real estate magnate who has been projected by Forbes.com to have a net worth of more than $4 billion.

The Lerners took over the Nationals from Major League Baseball in 2006, the year after the club was moved from Montreal to Washington.

Nationals general manager Mike Rizzo informed the team of Lerner’s surgery and condition Thursday night before their 2-1 win over San Diego, The Post reported, citing a phone interview with the GM.

“It’s been difficult to explain to players, to staff, to everybody,” Rizzo said, according to The Post. “They want to be private about it, and that’s their right. But his absence was noticed. Not having him in the draft room; he’s always in the draft room. Not having him at the trade deadline, when you’re talking to Mr. Lerner and the group 20 times a day. I know they were keeping him abreast, and he had other things on his mind, but I missed him. It was sad. I was bummed out about it.”

Said Nats first baseman Ryan Zimmerman, “Anytime you hear that about anyone it’s tough, especially someone like Mark. He’s around all the time. He’s not only an owner, but he’s a huge fan of D.C. baseball. I know it’s probably killing him more than anyone to not be able to be around. I think the news is good news, for the most part. It’s obviously going to be tough for him and we’ll be here to support him with anything he needs.”

Lerner said he was diagnosed in January with a rare type of cancer called spindle cell sarcoma that attacks connective tissue. The cancer was found in his left leg above the knee, Lerner said.

“The radiation treatment eventually caused the wound not to heal properly,” Lerner wrote.

Lerner said in the letter that his close-knit family has been a boon in his recovery.

“I’ve been very blessed with my wonderful wife Judy, who has never left my side, our great kids, amazing family and close friends,” Lerner wrote. “I really appreciate everyone respecting our family’s privacy as we’ve gone through this. I’m not sure of the timeline yet, but you know I’ll be at Nationals Park as soon as I possibly can.”

Information from The Associated Press was used in this report.

See the original post:
Nationals owner Mark Lerner had leg amputated to remove cancer – ESPN

Posted in Cancer | Comments Off on Nationals owner Mark Lerner had leg amputated to remove cancer – ESPN

Mother, Daughter Kayaking Delaware River In Support Of Breast … – CBS Philly

Posted: at 2:41 pm

PHILADELPHIA (CBS) A New Hampshire woman and her daughter are kayaking the entirety of the Delaware River from New York to Baltimore to raise support for breast cancer research. The pair made their first of 3-stops in our area Thursday afternoon. KYWs Dan Wing caught up with the pair in Lambertville, N.J.

Choate and her daughter will stop in Trenton Friday afternoon, and then in Burlington County Saturday as part of their journey, which you can follow on her Kayak River of Life Facebook page.

In 2003, Carolyn Choate was told she only had three years to live after being diagnosed with breast cancer. After two mastectomies, chemo, and drug treatments the now 59-year-old is kayaking to raise support for Breast Cancer Research, and raise funds for an endowment at the University of Maryland in the name of Dr. Angela Brodie, who holds a special place in Choates heart as her research discovered aromatase-inhibitors, which were key in Choates treatment.

In 2014, Choate reached out to Dr. Brodie by email.

And I said Dr. Brodie, if this gets to you, I just you to know how grateful and how thankful I am for saving my life and the life of millions of women around the world, she says.

The two quickly became friends, however Dr. Brodie passed earlier this summer.

Choate now hopes to raise awareness of her work through her kayaking trip and through the endowment in her name.

Go here to read the rest:
Mother, Daughter Kayaking Delaware River In Support Of Breast … – CBS Philly

Posted in Cancer Research | Comments Off on Mother, Daughter Kayaking Delaware River In Support Of Breast … – CBS Philly

Locals set to rally, walk for Lung Cancer Research – Tacoma Weekly

Posted: at 2:41 pm

Hundredsof local residents are joining forces to fight lung cancer, united in the belief that surviving lung cancer should be the expectation, not the exception. The Puget Sound Free to Breathe 5K run/walk and one-mile walk presented by Korum for Kids Foundation will take placeSaturday, Sept. 9at Wright Park, 501 S. I St. This year is the 10thanniversary of the event. All proceeds from the event support Free to Breathe, a lung cancer research and advocacy organization dedicated to increasing lung cancer survival.

By fundraising and joining us on event day, you are bringing hope to those affected by the disease and their families, said volunteer event chair Julie Drobny of Tacoma. Lung cancer claims more lives each year than breast, colon and prostate cancer combined, yet these three cancers receive more research funding. More treatment options are needed, and the innovative research were funding through the fundraising efforts of our community can help ensure everyone diagnosed with the disease has a fighting chance.

The Free to Breathe events community has raised over $16 million to support groundbreaking research and educational programs since 2005. Funds raised support life-saving lung cancer research, promote access to clinical trials while building and empowering the lung cancer community.

Last year, community members, teams, and companies across the region supported the Puget Sound Free to Breathe 5K run/walk and one-mile walk by raising over $82,000. Event chairs hope to surpass that total in 2017, which will go a long way in supporting programs specifically designed to ensure that more patients become survivors. Every dollar counts to the more than 224,000 people diagnosed in the U.S with lung cancer each year. In Washington alone, an estimated 4,390 residents will be diagnosed with lung cancer in 2017.

The day will include an opening rally, closing rally, prize drawing, music from a local DJ, kids activities and fun for the whole family. Special recognition will be given to top finishers and fundraisers. Gather your squad, and join us for an inspiring day focused on doubling lung cancer survival. To register and begin fundraising, visitwww.freetobreathe.org/pugetsound.

Like Loading…

Go here to see the original:
Locals set to rally, walk for Lung Cancer Research – Tacoma Weekly

Posted in Cancer Research | Comments Off on Locals set to rally, walk for Lung Cancer Research – Tacoma Weekly

Vitamin C could help genes kill blood cancer stem cells – Economic Times

Posted: at 2:40 pm

WASHINGTON D.C: Good news! A study has recently revealed that vitamin C may tell faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers.

According to researchers, certain genetic changes are known to reduce the ability of an enzyme called TET2 to encourage stem cells to become mature blood cells, which eventually die, in many patients with certain kinds of leukemia.

The new study found that vitamin C activated TET2 function in mice engineered to be deficient in the enzyme.

Corresponding study author Benjamin G. Neel said, “We’re excited by the prospect that high-dose vitamin C might become a safe treatment for blood diseases caused by TET2-deficient leukemia stem cells, most likely in combination with other targeted therapies.”

The results suggested that changes in the genetic code (mutations) that reduce TET2 function are found in 10 percent of patients with acute myeloid leukemia (AML), 30 percent of those with a form of pre-leukemia called myelodysplastic syndrome, and in nearly 50 percent of patients with chronic myelomonocytic leukemia.

The study results revolve around the relationship between TET2 and cytosine, one of the four nucleic acid “letters” that comprise the DNA code in genes.

To determine the effect of mutations that reduce TET2 function in abnormal stem cells, the team genetically engineered mice such that the scientists could switch the TET2 gene on or off.

The findings indicated that vitamin C did the same thing as restoring TET2 function genetically. By promoting DNA demethylation, high-dose vitamin C treatment induced stem cells to mature, and also suppressed the growth of leukemia cancer stem cells from human patients implanted in mice.

“Interestingly, we also found that vitamin C treatment had an effect on leukemic stem cells that resembled damage to their DNA,” said first study author Luisa Cimmino.

“For this reason, we decided to combine vitamin C with a PARP inhibitor, a drug type known to cause cancer cell death by blocking the repair of DNA damage, and already approved for treating certain patients with ovarian cancer,” Cimmino added.

The findings appear in journal Cell.

Original post:
Vitamin C could help genes kill blood cancer stem cells – Economic Times

Posted in Stem Cell Cancer | Comments Off on Vitamin C could help genes kill blood cancer stem cells – Economic Times

New treatment for deadly blood cancers expected to be approved soon – STLtoday.com

Posted: at 2:40 pm

Cancer doctors in St. Louis are ready to use a new therapy using a patients own blood to fight their disease.

The therapy, called CAR-T, for chimeric antigen receptor T-cell, involves removing immune cells from the blood, reprogramming them genetically to find and destroy cancer cells and then returning the immune cells to the patient. So far, the therapy has been tested on patients with hard-to-treat advanced blood cancers such as leukemia, lymphoma and myeloma that kill more than 58,000 Americans a year.

In one small study sponsored by Novartis Pharmaceuticals, 52 of 63 pediatric and young adult patients with relapsed acute lymphoblastic leukemia went into remission after undergoing CAR-T therapy. The 11 other patients died, seven from the cancer and four from side effects of the treatment.

Acute lymphoblastic leukemia, the most common childhood cancer, can be effectively treated with chemotherapy, but survival rates drop below 30 percent if the patient relapses. Candidates for CAR-T therapy include an estimated 600 children each year who relapse or do not respond to traditional chemotherapy.

At least 16 of the 20 people who have received CAR-T therapy for leukemia or lymphoma through clinical trials at Washington Universitys Siteman Cancer Center have seen their cancers disappear after treatment.

Ive never seen anything in cancer history with that kind of response, said Dr. Armin Ghobadi, an assistant professor in oncology at Washington University. These are the basically bad, incurable, deadly, unstoppable cancers and patients usually die quickly when we dont give them this treatment.

If approved as expected by the Food and Drug Administration, CAR-T therapy could be available locally within a year. Currently no patients at St. Louis Childrens Hospital qualify for the therapy, but patients are expected to come from neighboring states, said Dr. Robert Hayashi, director of hematology/oncology at the hospital.

This advancement is significant and has already demonstrated that it can be an effective form of therapy, Hayashi said. The ability of being able to show a clear success opens the door in terms of what other cancers can benefit from this exact same strategy.

So far the therapy has shown the most effectiveness in cancers of the blood. Another small trial in China involved 33 out of 35 patients experiencing remission from relapsing multiple myeloma, a plasma cancer, after receiving CAR-T therapy.

For decades, scientists have tried to corral the bodys immune system to fight cancer the way it attacks harmful bacteria or viruses. The immune system has a harder time recognizing cancer cells, allowing them to grow. Re-engineering immune cells to fight cancer cells is like turning on the cars headlights at night, Ghobadi said.

A main challenge with CAR-T therapy is the length of time it can take to reprogram the patients blood cells up to three weeks. Researchers are studying ways to reduce the time frame, including engineering universal CAR-T cells derived from donor blood or umbilical cord blood.

CAR-T therapy is expected to cost up to $500,000 for a one-time treatment. Scientists at Washington University are working to engineer the cells in-house, which could lower the price.

The side effects of the treatment can be severe as the immune system is amplified to fight cancer. A complication called cytokine release syndrome can cause life-threatening reactions including brain swelling. In early studies, one-third to one-half of patients treated with CAR-T therapy developed the syndrome. Because patients will need to be closely monitored, drug companies will limit the treatments availability to a few dozen cancer centers nationwide, including Siteman.

Marie Miceli, 64, was one of the first to be treated with CAR-T cell therapy in a trial at Siteman after several rounds of chemotherapy and a stem cell replacement failed to knock out non-Hodgkin lymphoma.

A year later, Miceli is in remission and just celebrated the birth of her fourth grandchild. Miceli, a real estate agent and branch manager at Berkshire Hathaway in St. Louis, said she was blessed to receive the experimental treatment.

You have to trust those doctors and have faith, she said.

Read the original post:
New treatment for deadly blood cancers expected to be approved soon – STLtoday.com

Posted in Stem Cell Cancer | Comments Off on New treatment for deadly blood cancers expected to be approved soon – STLtoday.com

Cancer Genetics pays $12M for Australian CRO vivoPharm – FierceBiotech

Posted: August 18, 2017 at 12:44 pm

U.S. oncology specialist Cancer Genetics will pay $12 million to buy out Australian contract research organization vivoPharm as it looks to bolster its offerings.

Cancer Genetics (CGI) says the deal will boost its position as a premier leader for oncology discovery, in vivo and in vitro drug development and early phase clinical trial testing for biotechnology and pharmaceutical companies.

It buys into vivoPharm, a firm that has spent 10 years offering discovery and preclinical services to support drug development, target validation and biomarker analysis, with a big focus on immuno-oncology.

The CRO currently works with more than 40 biopharmas across five continents, in more than 55 studies and trials. Its led by Ralf Brandt, who will be fully integrated as the flagship in CGIs discovery services offering, according to its new owner, serving as the president of this unit.

The deal closed this week, and sees its 32 staffers subsumed into CGI. The price paid, $12 million, includes $1.2 million in cash, with the remaining 90% in the form of shares of CGI common stock. The company has also signed an equity financing deal for up to $16 million to fund the takeover.

The acquisition is expected to be immediately accretive, adding both revenue and income, CGI said in a statement.

The combination of capabilities is expected to create considerable business opportunities in both pre-clinical studies and immuno-oncology clinical trials, to further accelerate CGIs strategy to be the premier partner of choice for oncology innovation and development from bench to bedside.

See the original post:
Cancer Genetics pays $12M for Australian CRO vivoPharm – FierceBiotech

Posted in Cancer Genetics | Comments Off on Cancer Genetics pays $12M for Australian CRO vivoPharm – FierceBiotech

Page 4«..3456..1020..»